Eli Lilly and Company (LLY)vsNuvation Bio Inc (NUVB)
LLY
Eli Lilly and Company
$1,137.76
+1.98%
HEALTHCARE · Cap: $994.92B
NUVB
Nuvation Bio Inc
$6.07
-3.34%
HEALTHCARE · Cap: $2.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 46790% more annual revenue ($79.67B vs $169.90M). LLY leads profitability with a 33.5% profit margin vs -88.2%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
NUVB
Avoid28
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Revenue surging 556.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 29.9x book value
Trading at 8.3x book value
0.0% earnings growth
ROE of -45.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : NUVB
The strongest argument for NUVB centers on Revenue Growth. Revenue growth of 556.0% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : NUVB
The primary concerns for NUVB are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
LLY profiles as a growth stock while NUVB is a hypergrowth play — different risk/reward profiles.
NUVB carries more volatility with a beta of 1.53 — expect wider price swings.
NUVB is growing revenue faster at 556.0% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 28/100), backed by strong 33.5% margins and 47.7% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Nuvation Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology. The company is headquartered in New York, New York.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?